Wiley Matthew T.
Wiley Matthew T., CCO, reported a transaction classified as grant at Definium Therapeutics, Inc. involving 125000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 362133.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 14, 2026
- Filing date
- Sep 14, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
DFTX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001193125-26-389890 Common Shares
- Transaction date
- Sep 14, 2026 Filed Sep 14, 2026, 12:30 PM · 0d delay
- Shares
- 125,000 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 362,133 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-12 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 0
Filing reported within two business days of the transaction. - grant_or_award-22 points
transaction_code = A
Grant or award transactions are scheduled compensation, not discretionary.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Commercial Officer
- F1
The common shares represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through Ma…
0 other transactions
0 recent txs